Watch Demo

Global Hemato Oncology Testing Industry

Global Hemato Oncology Testing Industry

  • Publish Date:October 2022

  • Number of Pages:92

  • Report ID:6031778

  • Format:PDF

  • Publisher:Global Industry Analysts

$ 5600

Summary

Abstract:

What’s New for 2022?

Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year

Global Hemato Oncology Testing Market to Reach $8.3 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Hemato Oncology Testing estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$8.3 Billion by 2027, growing at aCAGR of 18.1% over the period 2020-2027. Services, one of the segments analyzed in the report, is projected to record 17.2% CAGR and reach US$5.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Assay Kits segment is readjusted to a revised 19.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $708.6 Million, While China is Forecast to Grow at 23.4% CAGR

The Hemato Oncology Testing market in the U.S. is estimated at US$708.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2027 trailing a CAGR of 23.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.1% and 16.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 14.5% CAGR.

Select Competitors (Total 36 Featured) -
Abbott Laboratories
Adaptive Biotechnologies
Archerdx, Inc.
Arup Laboratories, Inc.
Asuragen, Inc.
Bio-Rad Laboratories, Inc.
F. Hoffman-La Roche Ltd.
Illumina, Inc.
Invivoscribe, Inc.
Molecularmd (Subsidiary of Icon PLC)
Qiagen N.V.
Sanofi SA
Thermo Fisher Scientific, Inc.

Table of contents

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Hemato Oncology Testing - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Hemato Oncology Testing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Hemato Oncology Testing
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Services by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Services by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Services by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for Assay
Kits by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Assay Kits by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Assay Kits by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for PCR
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for PCR by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for PCR by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for IHC
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for IHC by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for IHC by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for NGS
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for NGS by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for NGS by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for
Cytogenetics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Cytogenetics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Cytogenetics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Other Technologies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Other Technologies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Other Technologies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 25: World Hemato Oncology Testing Market Analysis of
Annual Sales in US$ Million for Years 2012 through 2027

Table 26: World Recent Past, Current & Future Analysis for
Hodgkin Lymphoma by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 27: World Historic Review for Hodgkin Lymphoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 28: World 15-Year Perspective for Hodgkin Lymphoma by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 29: World Recent Past, Current & Future Analysis for
Other Cancer Types by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 30: World Historic Review for Other Cancer Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 31: World 15-Year Perspective for Other Cancer Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 32: World Recent Past, Current & Future Analysis for
Leukemia by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 33: World Historic Review for Leukemia by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 34: World 15-Year Perspective for Leukemia by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 35: World Recent Past, Current & Future Analysis for
Lymphoma by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 36: World Historic Review for Lymphoma by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 37: World 15-Year Perspective for Lymphoma by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Hemato Oncology Testing Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2022 (E)
Table 38: USA Recent Past, Current & Future Analysis for Hemato
Oncology Testing by Component - Services and Assay Kits -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 39: USA Historic Review for Hemato Oncology Testing by
Component - Services and Assay Kits Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 40: USA 15-Year Perspective for Hemato Oncology Testing
by Component - Percentage Breakdown of Value Sales for Services
and Assay Kits for the Years 2012, 2021 & 2027

Table 41: USA Recent Past, Current & Future Analysis for Hemato
Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics
and Other Technologies - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 42: USA Historic Review for Hemato Oncology Testing by
Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 43: USA 15-Year Perspective for Hemato Oncology Testing
by Technology - Percentage Breakdown of Value Sales for PCR,
IHC, NGS, Cytogenetics and Other Technologies for the Years
2012, 2021 & 2027

Table 44: USA Recent Past, Current & Future Analysis for Hemato
Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other
Cancer Types, Leukemia and Lymphoma - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 45: USA Historic Review for Hemato Oncology Testing by
Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia
and Lymphoma Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 46: USA 15-Year Perspective for Hemato Oncology Testing
by Cancer Type - Percentage Breakdown of Value Sales for
Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for
the Years 2012, 2021 & 2027

CANADA
Table 47: Canada Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Component - Services and Assay Kits -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 48: Canada Historic Review for Hemato Oncology Testing by
Component - Services and Assay Kits Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 49: Canada 15-Year Perspective for Hemato Oncology
Testing by Component - Percentage Breakdown of Value Sales for
Services and Assay Kits for the Years 2012, 2021 & 2027

Table 50: Canada Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Technology - PCR, IHC, NGS,
Cytogenetics and Other Technologies - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 51: Canada Historic Review for Hemato Oncology Testing by
Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 52: Canada 15-Year Perspective for Hemato Oncology
Testing by Technology - Percentage Breakdown of Value Sales for
PCR, IHC, NGS, Cytogenetics and Other Technologies for the
Years 2012, 2021 & 2027

Table 53: Canada Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma,
Other Cancer Types, Leukemia and Lymphoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 54: Canada Historic Review for Hemato Oncology Testing by
Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia
and Lymphoma Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 55: Canada 15-Year Perspective for Hemato Oncology
Testing by Cancer Type - Percentage Breakdown of Value Sales
for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma
for the Years 2012, 2021 & 2027

JAPAN
Hemato Oncology Testing Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2022 (E)
Table 56: Japan Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Component - Services and Assay Kits -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 57: Japan Historic Review for Hemato Oncology Testing by
Component - Services and Assay Kits Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 58: Japan 15-Year Perspective for Hemato Oncology Testing
by Component - Percentage Breakdown of Value Sales for Services
and Assay Kits for the Years 2012, 2021 & 2027

Table 59: Japan Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Technology - PCR, IHC, NGS,
Cytogenetics and Other Technologies - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 60: Japan Historic Review for Hemato Oncology Testing by
Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 61: Japan 15-Year Perspective for Hemato Oncology Testing
by Technology - Percentage Breakdown of Value Sales for PCR,
IHC, NGS, Cytogenetics and Other Technologies for the Years
2012, 2021 & 2027

Table 62: Japan Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma,
Other Cancer Types, Leukemia and Lymphoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 63: Japan Historic Review for Hemato Oncology Testing by
Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia
and Lymphoma Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 64: Japan 15-Year Perspective for Hemato Oncology Testing
by Cancer Type - Percentage Breakdown of Value Sales for
Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for
the Years 2012, 2021 & 2027

CHINA
Hemato Oncology Testing Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2022 (E)
Table 65: China Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Component - Services and Assay Kits -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 66: China Historic Review for Hemato Oncology Testing by
Component - Services and Assay Kits Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 67: China 15-Year Perspective for Hemato Oncology Testing
by Component - Percentage Breakdown of Value Sales for Services
and Assay Kits for the Years 2012, 2021 & 2027

Table 68: China Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Technology - PCR, IHC, NGS,
Cytogenetics and Other Technologies - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 69: China Historic Review for Hemato Oncology Testing by
Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 70: China 15-Year Perspective for Hemato Oncology Testing
by Technology - Percentage Breakdown of Value Sales for PCR,
IHC, NGS, Cytogenetics and Other Technologies for the Years
2012, 2021 & 2027

Table 71: China Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma,
Other Cancer Types, Leukemia and Lymphoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 72: China Historic Review for Hemato Oncology Testing by
Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia
and Lymphoma Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 73: China 15-Year Perspective for Hemato Oncology Testing
by Cancer Type - Percentage Breakdown of Value Sales for
Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for
the Years 2012, 2021 & 2027

EUROPE
Hemato Oncology Testing Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2022 (E)
Table 74: Europe Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 75: Europe Historic Review for Hemato Oncology Testing by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 76: Europe 15-Year Perspective for Hemato Oncology
Testing by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2012, 2021 & 2027

Table 77: Europe Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Component - Services and Assay Kits -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 78: Europe Historic Review for Hemato Oncology Testing by
Component - Services and Assay Kits Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 79: Europe 15-Year Perspective for Hemato Oncology
Testing by Component - Percentage Breakdown of Value Sales for
Services and Assay Kits for the Years 2012, 2021 & 2027

Table 80: Europe Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Technology - PCR, IHC, NGS,
Cytogenetics and Other Technologies - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 81: Europe Historic Review for Hemato Oncology Testing by
Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 82: Europe 15-Year Perspective for Hemato Oncology
Testing by Technology - Percentage Breakdown of Value Sales for
PCR, IHC, NGS, Cytogenetics and Other Technologies for the
Years 2012, 2021 & 2027

Table 83: Europe Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma,
Other Cancer Types, Leukemia and Lymphoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 84: Europe Historic Review for Hemato Oncology Testing by
Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia
and Lymphoma Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 85: Europe 15-Year Perspective for Hemato Oncology
Testing by Cancer Type - Percentage Breakdown of Value Sales
for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma
for the Years 2012, 2021 & 2027

FRANCE
Hemato Oncology Testing Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2022 (E)
Table 86: France Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Component - Services and Assay Kits -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 87: France Historic Review for Hemato Oncology Testing by
Component - Services and Assay Kits Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 88: France 15-Year Perspective for Hemato Oncology
Testing by Component - Percentage Breakdown of Value Sales for
Services and Assay Kits for the Years 2012, 2021 & 2027

Table 89: France Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Technology - PCR, IHC, NGS,
Cytogenetics and Other Technologies - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 90: France Historic Review for Hemato Oncology Testing by
Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 91: France 15-Year Perspective for Hemato Oncology
Testing by Technology - Percentage Breakdown of Value Sales for
PCR, IHC, NGS, Cytogenetics and Other Technologies for the
Years 2012, 2021 & 2027

Table 92: France Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma,
Other Cancer Types, Leukemia and Lymphoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 93: France Historic Review for Hemato Oncology Testing by
Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia
and Lymphoma Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 94: France 15-Year Perspective for Hemato Oncology
Testing by Cancer Type - Percentage Breakdown of Value Sales
for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma
for the Years 2012, 2021 & 2027

GERMANY
Hemato Oncology Testing Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2022 (E)
Table 95: Germany Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Component - Services and Assay Kits -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 96: Germany Historic Review for Hemato Oncology Testing
by Component - Services and Assay Kits Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 97: Germany 15-Year Perspective for Hemato Oncology
Testing by Component - Percentage Breakdown of Value Sales for
Services and Assay Kits for the Years 2012, 2021 & 2027

Table 98: Germany Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Technology - PCR, IHC, NGS,
Cytogenetics and Other Technologies - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 99: Germany Historic Review for Hemato Oncology Testing
by Technology - PCR, IHC, NGS, Cytogenetics and Other
Technologies Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 100: Germany 15-Year Perspective for Hemato Oncology
Testing by Technology - Percentage Breakdown of Value Sales for
PCR, IHC, NGS, Cytogenetics and Other Technologies for the
Years 2012, 2021 & 2027

Table 101: Germany Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma,
Other Cancer Types, Leukemia and Lymphoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 102: Germany Historic Review for Hemato Oncology Testing
by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia
and Lymphoma Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 103: Germany 15-Year Perspective for Hemato Oncology
Testing by Cancer Type - Percentage Breakdown of Value Sales
for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma
for the Years 2012, 2021 & 2027

ITALY
Table 104: Italy Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Component - Services and Assay Kits -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 105: Italy Historic Review for Hemato Oncology Testing by
Component - Services and Assay Kits Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 106: Italy 15-Year Perspective for Hemato Oncology
Testing by Component - Percentage Breakdown of Value Sales for
Services and Assay Kits for the Years 2012, 2021 & 2027

Table 107: Italy Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Technology - PCR, IHC, NGS,
Cytogenetics and Other Technologies - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 108: Italy Historic Review for Hemato Oncology Testing by
Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 109: Italy 15-Year Perspective for Hemato Oncology
Testing by Technology - Percentage Breakdown of Value Sales for
PCR, IHC, NGS, Cytogenetics and Other Technologies for the
Years 2012, 2021 & 2027

Table 110: Italy Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma,
Other Cancer Types, Leukemia and Lymphoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 111: Italy Historic Review for Hemato Oncology Testing by
Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia
and Lymphoma Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 112: Italy 15-Year Perspective for Hemato Oncology
Testing by Cancer Type - Percentage Breakdown of Value Sales
for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma
for the Years 2012, 2021 & 2027

UNITED KINGDOM
Hemato Oncology Testing Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2022 (E)
Table 113: UK Recent Past, Current & Future Analysis for Hemato
Oncology Testing by Component - Services and Assay Kits -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 114: UK Historic Review for Hemato Oncology Testing by
Component - Services and Assay Kits Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 115: UK 15-Year Perspective for Hemato Oncology Testing
by Component - Percentage Breakdown of Value Sales for Services
and Assay Kits for the Years 2012, 2021 & 2027

Table 116: UK Recent Past, Current & Future Analysis for Hemato
Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics
and Other Technologies - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 117: UK Historic Review for Hemato Oncology Testing by
Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 118: UK 15-Year Perspective for Hemato Oncology Testing
by Technology - Percentage Breakdown of Value Sales for PCR,
IHC, NGS, Cytogenetics and Other Technologies for the Years
2012, 2021 & 2027

Table 119: UK Recent Past, Current & Future Analysis for Hemato
Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other
Cancer Types, Leukemia and Lymphoma - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 120: UK Historic Review for Hemato Oncology Testing by
Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia
and Lymphoma Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 121: UK 15-Year Perspective for Hemato Oncology Testing
by Cancer Type - Percentage Breakdown of Value Sales for
Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for
the Years 2012, 2021 & 2027

SPAIN
Table 122: Spain Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Component - Services and Assay Kits -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 123: Spain Historic Review for Hemato Oncology Testing by
Component - Services and Assay Kits Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 124: Spain 15-Year Perspective for Hemato Oncology
Testing by Component - Percentage Breakdown of Value Sales for
Services and Assay Kits for the Years 2012, 2021 & 2027

Table 125: Spain Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Technology - PCR, IHC, NGS,
Cytogenetics and Other Technologies - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 126: Spain Historic Review for Hemato Oncology Testing by
Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 127: Spain 15-Year Perspective for Hemato Oncology
Testing by Technology - Percentage Breakdown of Value Sales for
PCR, IHC, NGS, Cytogenetics and Other Technologies for the
Years 2012, 2021 & 2027

Table 128: Spain Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma,
Other Cancer Types, Leukemia and Lymphoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 129: Spain Historic Review for Hemato Oncology Testing by
Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia
and Lymphoma Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 130: Spain 15-Year Perspective for Hemato Oncology
Testing by Cancer Type - Percentage Breakdown of Value Sales
for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma
for the Years 2012, 2021 & 2027

RUSSIA
Table 131: Russia Recent Past, Current & Future Analysis for
Hemato Oncology Testing by Component - Services and Assay Kits -

Please contact our Customer Support Center to get the complete Table of Contents

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.